Chimerix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Chimerix (NASDAQ:CMRX) has announced that its Compensation Committee granted inducement awards to three new employees on December 2, 2024. The awards consist of non-statutory stock options to purchase up to 385,000 shares of common stock. The options have a 10-year term with an exercise price equal to Chimerix's closing trading price on the grant date.
The vesting schedule spans four years, with 25% vesting after the first year and the remaining 75% vesting monthly over the following three years. While subject to the terms of Chimerix's 2024 Equity Incentive Plan, these grants were made outside of it. The company, focused on developing medicines for deadly diseases, is currently advancing dordaviprone (ONC201) for H3 K27M-mutant glioma and conducting Phase 1 studies of ONC206.
Chimerix (NASDAQ:CMRX) ha annunciato che il suo Comitato per la Compensazione ha concesso premi di indennità a tre nuovi dipendenti il 2 dicembre 2024. I premi consistono in opzioni su azioni non statutarie per acquistare fino a 385.000 azioni ordinarie. Le opzioni hanno una durata di 10 anni con un prezzo di esercizio pari al prezzo di chiusura delle azioni di Chimerix alla data di concessione.
Il piano di maturazione si estende per quattro anni, con il 25% che matura dopo il primo anno e il rimanente 75% che matura mensilmente nei successivi tre anni. Pur essendo soggetti ai termini del Piano di Incentivi Azionari 2024 di Chimerix, questi premi sono stati concessi al di fuori di esso. L'azienda, focalizzata nello sviluppo di farmaci per malattie mortali, sta attualmente promuovendo dordaviprone (ONC201) per il glioma mutante H3 K27M e conducendo studi di Fase 1 su ONC206.
Chimerix (NASDAQ:CMRX) ha anunciado que su Comité de Compensación otorgó premios de incentivo a tres nuevos empleados el 2 de diciembre de 2024. Los premios consisten en opciones sobre acciones no estatutarias para comprar hasta 385,000 acciones ordinarias. Las opciones tienen un plazo de 10 años con un precio de ejercicio igual al precio de cierre de Chimerix en la fecha de concesión.
El cronograma de adquisición se extiende a lo largo de cuatro años, con un 25% adquirible después del primer año y el 75% restante adquirible mensualmente durante los tres años siguientes. Aunque están sujetos a los términos del Plan de Incentivos de Capital 2024 de Chimerix, estos premios se otorgaron fuera de este. La empresa, centrada en el desarrollo de medicamentos para enfermedades mortales, está avanzando en dordaviprone (ONC201) para glioma mutante H3 K27M y realizando estudios de Fase 1 de ONC206.
치메릭스 (NASDAQ:CMRX)는 2024년 12월 2일 세 명의 새로운 직원에게 유도 보상을 부여했다고 발표했습니다. 이 보상은 최대 385,000주에 대한 비법적 주식 옵션으로 구성됩니다. 옵션은 10년의 기간을 가지고 있으며, 기념일의 종가와 동일한 행사가격을 갖습니다.
베스팅 일정은 4년간 이어지며, 첫 해에 25%가 베스팅되고 나머지 75%는 다음 3년 동안 매달 베스팅됩니다. 이 부여는 치메릭스의 2024년 자본 인센티브 계획의 조건을 따르지만, 이와는 별도로 이루어졌습니다. 치메릭스는 치명적인 질병에 대한 의약품 개발에 집중하고 있으며, 현재 H3 K27M 변이 교모세포종을 위한 도르다비프론(ONC201)을 발전시키고 있으며, ONC206의 1상 연구를 진행하고 있습니다.
Chimerix (NASDAQ:CMRX) a annoncé que son Comité de rémunération a accordé des primes d'incitation à trois nouveaux employés le 2 décembre 2024. Les primes consistent en des options d'achat d'actions non statutaire pour acheter jusqu'à 385 000 actions ordinaires. Les options ont une durée de 10 ans avec un prix d'exercice égal au prix de clôture de Chimerix à la date de l'octroi.
Le calendrier d'acquisition s'étend sur quatre ans, avec 25 % d'acquisition après la première année et les 75 % restants acquérant mensuellement au cours des trois années suivantes. Bien qu'étant soumis aux termes du Plan d'incitation au capital 2024 de Chimerix, ces primes ont été accordées en dehors de celui-ci. L'entreprise, axée sur le développement de médicaments contre les maladies mortelles, fait actuellement avancer le dordaviprone (ONC201) pour le gliome mutant H3 K27M et mène des études de Phase 1 sur ONC206.
Chimerix (NASDAQ:CMRX) hat bekannt gegeben, dass sein Vergütungsausschuss am 2. Dezember 2024 Anreizprämien an drei neue Mitarbeiter vergeben hat. Die Prämien bestehen aus nicht-statutären Aktienoptionen zum Kauf von bis zu 385.000 Stammaktien. Die Optionen haben eine Laufzeit von 10 Jahren und einen Ausübungspreis, der dem Schlusskurs von Chimerix am Tag der Gewährung entspricht.
Der Vesting-Zeitplan erstreckt sich über vier Jahre, wobei 25 % nach dem ersten Jahr und die verbleibenden 75 % monatlich über die folgenden drei Jahre vervestet werden. Obwohl diese Zuwendungen den Bedingungen des Chimerix 2024 Equity Incentive Plans unterliegen, wurden sie außerhalb dieses Plans gewährt. Das Unternehmen, das sich auf die Entwicklung von Medikamenten gegen tödliche Krankheiten konzentriert, fördert derzeit dordaviprone (ONC201) für H3 K27M-mutierte Gliome und führt Phase-1-Studien zu ONC206 durch.
- None.
- None.
DURHAM, N.C., Dec. 06, 2024 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), today announced that on December 2, 2024, the Compensation Committee of Chimerix’s Board of Directors granted inducement awards to three new employees of non-statutory stock options to purchase up to a total of 385,000 shares of Chimerix’s common stock. The Compensation Committee of Chimerix’s Board of Directors approved the awards as an inducement material to the new employees’ employment in accordance with Nasdaq Listing rule 5635(c)(4).
The stock options have an exercise price per share equal to Chimerix’s closing trading price as of the grant date. The stock options have a 10-year term and will vest over four years, with one-fourth vesting on the one-year anniversary of the date of hire and the remaining three-fourths vesting over the following three years in equal monthly installments. The stock options are subject to the terms of Chimerix’s 2024 Equity Incentive Plan but were granted outside of the 2024 Equity Incentive Plan.
Chimerix is a biopharmaceutical company with a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The Company’s most advanced clinical-stage development program, dordaviprone (ONC201), is in development for H3 K27M-mutant glioma. The Company is conducting Phase 1 dose escalation studies of ONC206 to evaluate safety and PK data.
CONTACTS:
Will O’Connor
Stern Investor Relations
212-362-1200
ir@chimerix.com
will@sternir.com
FAQ
How many shares were granted in Chimerix's (CMRX) December 2024 inducement awards?
What is the vesting schedule for Chimerix's (CMRX) December 2024 stock option grants?
What are Chimerix's (CMRX) current clinical development programs as of December 2024?
